Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44.08 CHF | +2.55% |
|
-.--% | -6.91% |
09:14pm | Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval | MT |
07:27pm | US FDA approves Bristol Myers' colorectal cancer therapy | RE |
Business Summary
The United States account for 70.1% of net sales.
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 46,159 | 100.0 % | 45,006 | 100.0 % | -2.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
70.1
%
| 31,828 | 69.0 % | 31,555 | 70.1 % | -0.86% |
International
28.3
%
| 13,497 | 29.2 % | 12,752 | 28.3 % | -5.52% |
Other
1.6
%
| 834 | 1.8 % | 699 | 1.6 % | -16.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 31/01/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 31/12/02 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/12/18 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 31/10/19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 31/03/16 |
Derica Rice
BRD | Director/Board Member | 59 | 31/08/20 |
Paula Price
BRD | Director/Board Member | 62 | 31/08/20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 20/02/17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 19/11/19 |
Chief Executive Officer | 53 | 31/01/15 | |
Julia Haller
BRD | Director/Board Member | 69 | 19/11/19 |
Karen Vousden
BRD | Director/Board Member | 66 | 31/12/17 |
Director/Board Member | 56 | 31/05/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,923,100,096 | 2,024,918,592 ( 69.27 %) | 896,000,000 ( 30.65 %) | 69.27 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
5,075,304 | 5.31% | 136,322,665 $ | |
759,145 | 6.36% | 19,358,198 $ | |
COMPUGEN LTD. 5.31% | 4,757,058 | 5.31% | 10,322,816 $ |
CELULARITY INC. 5.49% | 1,195,327 | 5.49% | 3,717,467 $ |
Company contact information
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.com![address Bristol-Myers Squibb Company(BMY)](https://cdn.zonebourse.com/static/address/149358858.png)
Group companies
Name | Category and Sector |
---|---|
Bristol-Myers Squibb India Pvt Ltd.
![]() Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. is an Indian company that discovers, develops, and delivers medicines for immuno-oncology. The company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
![]() Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico. |
Pharmaceuticals: Major
|
Celgene Kappa Holdings LLC
| |
Bristol-Myers Squibb International Co. ULC
| |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH
| |
Seamair Insurance DAC
![]() Seamair Insurance DAC Insurance Brokers/ServicesFinance Part of Bristol Myers Squibb Co., Seamair Insurance DAC is an Irish company that provides insurance services. The company is based in Dublin, Ireland. |
Insurance Brokers/Services
|
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
![]() Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
|
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.84% | 798B | |
+41.51% | 633B | |
-5.04% | 356B | |
+19.63% | 328B | |
+10.42% | 304B | |
+17.66% | 244B | |
+3.39% | 227B | |
+10.75% | 216B | |
+7.34% | 166B |
- Stock Market
- Equities
- BMY Stock
- BMY Stock
- Company Bristol-Myers Squibb Company